Histopathological Grading and a Role of IHC in Grading of Phyllodes Tumor of Breast

Phyllodes tumor of breast are rare fibroepithelial neoplasms. It accounts for less than1% of all breast tumors1. In 1827, Chelius described this tumor for the first time. Johanner muller was the first person to use the term Cystosarcoma phyllodes (1838) 2. Phyllodes tumor was considered as benign till 1943. In 1943, the malignant potential of this tumor was reported by Cooper and Ackerman. In 1981, the term phyllodes tumor was adopted by WHO. It exhibit a varying biological behavior ranging from benign to highly aggressive malignant sarcomas. Malignant phyllodes tumor has a five year survival rate of 50 -60%. It has 65% chance of local recurrence and 10% chance of distant metastasis if treated conservatively. Phyllodes tumor has been classified as benign, borderline and malignant phyllodes based on histological features. The conventional histological features has many overlapping features resulting in difficult to grade the phyllodes tumor accurately.